Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Phio Pharmaceuticals Corp (PHIO)

Phio Pharmaceuticals Corp (PHIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,988
  • Shares Outstanding, K 13,532
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,790 K
  • 60-Month Beta 2.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.51
Trade PHIO with:

Options Overview

Details
  • Implied Volatility 115.48%
  • Historical Volatility 70.49%
  • IV Percentile 15%
  • IV Rank 5.71%
  • IV High 630.56% on 03/09/21
  • IV Low 84.28% on 04/13/21
  • Put/Call Vol Ratio 3.89
  • Today's Volume 93
  • Volume Avg (30-Day) 106
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 5,576
  • Open Int (30-Day) 2,776

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.33
  • Growth Rate Est. (year over year) +75,212.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.20 +4.09%
on 04/16/21
3.23 -29.10%
on 03/18/21
-0.83 (-26.60%)
since 03/16/21
3-Month
2.12 +8.02%
on 03/05/21
4.36 -47.48%
on 02/18/21
-0.62 (-21.31%)
since 01/15/21
52-Week
1.65 +38.79%
on 04/21/20
6.48 -64.66%
on 05/29/20
+0.38 (+19.90%)
since 04/16/20

Most Recent Stories

More News
Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1

, /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL)...

PHIO : 2.29 (-1.29%)
Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update

, /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™)...

RXII : 0.33 (unch)
PHIO : 2.29 (-1.29%)
Thinking about buying stock in Phunware, Sonim Technologies, AMC Entertainment, Phio Pharmaceuticals, or Blue Apron?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHUN, SONM, AMC, PHIO, and APRN.

PHIO : 2.29 (-1.29%)
PHUN : 1.4600 (-8.18%)
SONM : 0.6102 (-2.07%)
AMC : 9.33 (-5.76%)
APRN : 6.09 (-6.31%)
Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting

, /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™)...

RXII : 0.33 (unch)
PHIO : 2.29 (-1.29%)
Thinking about buying stock in Phio Pharmaceuticals, SRAX Inc, KemPharm, Avadel Pharmaceuticals, or Neovasc Inc?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHIO, SRAX, KMPH, AVDL, and NVCN.

NVCN.TO : 1.02 (-6.42%)
AVDL : 8.62 (+0.82%)
KMPH : 8.60 (-2.05%)
PHIO : 2.29 (-1.29%)
NVCN : 0.8042 (-6.22%)
SRAX : 4.19 (-4.34%)
Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies

, March 1, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering...

RXII : 0.33 (unch)
PHIO : 2.29 (-1.29%)
Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th

, /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™)...

PHIO : 2.29 (-1.29%)
Dow Slips From Record Pace as Listless Week Continues

Dow Slips From Record Pace as Listless Week Continues

TWLO : 385.24 (-1.19%)
RCII : 56.89 (-0.05%)
SAH : 50.49 (+0.18%)
NVAX : 227.35 (+12.50%)
PHIO : 2.29 (-1.29%)
EBAY : 64.93 (+0.89%)
WHR : 234.81 (+1.70%)
WMT : 140.61 (+0.32%)
CLSK : 18.94 (-10.07%)
BCOV : 21.42 (+1.04%)
Thinking about buying stock in Ampio Pharmaceuticals, Motus GI, Phio Pharmaceuticals, Novan, or Oncolytics Biotech?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMPE, MOTS, PHIO, NOVN, and ONCY.

AMPE : 1.5700 (unch)
MOTS : 0.9570 (-8.86%)
NOVN : 1.1000 (-7.56%)
ONCY : 2.99 (+2.05%)
PHIO : 2.29 (-1.29%)
Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market

, /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™)...

PHIO : 2.29 (-1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Phio Pharmaceuticals Corp is focused on developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform. The Company's pipeline consists of RXI-762 and RXI-804 which are in clinical stage. Phio Pharmaceuticals Corp, formerly known as RXi Pharmaceuticals Corporation,...

See More

Key Turning Points

3rd Resistance Point 2.46
2nd Resistance Point 2.39
1st Resistance Point 2.34
Last Price 2.29
1st Support Level 2.22
2nd Support Level 2.15
3rd Support Level 2.10

See More

52-Week High 6.48
Fibonacci 61.8% 4.63
Fibonacci 50% 4.07
Fibonacci 38.2% 3.50
Last Price 2.29
52-Week Low 1.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar